RxSight price target raised to $65 from $36 at Morgan Stanley

Morgan Stanley analyst Patrick Wood raised the firm’s price target on RxSight to $65 from $36 and keeps an Overweight rating on the shares. The firm said that the shares have had a strong run since the company’s earnings pre-announcement. Morgan Stanley added that it remains bullish on the ability of the Light Adjustable Lens to take meaningful shares and beat Wall Street numbers.